The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD. Methods We did a randomised, parallel group, double-blind, placebo-controlled trial of 20 mg memantine taken orally daily for 26 weeks in patients with FTD. Participants met Neary criteria for behavioural variant FTD (bvFTD) or semantic dementia and had characteristic brain atrophy. Use of acetylcholinesterase inhibitors was prohibited. Individuals were randomly assigned to receive either memantine or matched placebo tablets (1:1) in blocks of two and four patients. All patients and study personnel were masked to treatment assignment. Primary endpoints were the change in total NPI score and clinical global impression of change (CGIC) score after 26 weeks and were analysed by intention to treat. This study is registered with Clinicaltrials.gov, number NCT00545974. Findings Of 100 patients screened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients). Five (6%) patients discontinued, and 76 completed the 26-week treatment. Enrolment numbers were lower than planned because of many patients' preference to take memantine or cholinesterase inhibitors off-label rather than participate in a clinical trial. Memantine treatment had no effect on either the NPI (mean difference 2·2, 95% CI -3·9 to 8·3, p=0·47) or CGIC (mean difference 0·0, -0·4 to 0·4, p=0·90) after 26 weeks of treatment. Memantine was generally well tolerated; however, patients in the memantine group had more frequent cognitive adverse events (six patients) than those in the placebo group (one). Interpretation Memantine treatment showed no benefit in patients with FTD. These data do not support memantine use in FTD. Funding Forest Research Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise memantine, an NMDA receptor antagonist, approved for moderate to severe AD, has shown no benefit in patients with bvFTD [38].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Self-citationWeıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
Measurement of Functional Activities in Older Adults in the Community
PFEFFER, R. I., Kurosaki, T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,978
The Neuropsychiatric Inventory
Cummings, J. L. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.10s · Cited by 2,055
Bédard, M., Molloy, D. W., Squire, L., Dubois, S., Lever, J. A., & O'Donnell, M. (2001) · The Gerontologist · doi:10.1093/geront/41.5.652 · Cited by 1,691
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Schneider, L., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, ., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 646
Bedside Assessment of Executive Cognitive Impairment: The Executive Interview
Royall, D. R., Mahurin, R. K., & Gray, K. F. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb03646.x · Cited by 595
Cited by
Sorted by citations
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Self-citationRabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Self-citationO'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine
Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Deerlin, V. M. V., Lee, V. M. ‐., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1380-1 · Cited by 278
Self-citationMemantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245
Neurotransmitter deficits from frontotemporal lobar degeneration
Murley, A. G., & Rowe, J. B. (2017) · Brain · doi:10.1093/brain/awx327 · Cited by 211
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citationKnight, R., Khondoker, M. R., Magill, N., Stewart, R. J., & Landau, S. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000486546 · Cited by 169
Frontotemporal Dementia: diagnosis, Deficits and Management
Bott, N. T., Radke, A., Stephens, M. L., & Kramer, J. H. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.34 · Cited by 164
Self-citationTherapy and clinical trials in frontotemporal dementia: past, present, and future
Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 157
Self-citationWord retrieval therapies in primary progressive aphasia
Jokel, R., Graham, N., Rochon, E., & Leonard, C. (2014) · Aphasiology · doi:10.1080/02687038.2014.899306 · Cited by 125
Diagnosis and Management of Behavioral Variant Frontotemporal Dementia
Pressman, P., & Miller, B. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.006 · Cited by 127
Self-citationDevelopment of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Frontotemporal lobar degeneration: current perspectives
Kurz, A., Riedl, L., Mackenzie, I. R., Förstl, H., & Diehl‐Schmid, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s38706 · Cited by 123
Finger, E. C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000300 · Cited by 134
Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials
Staffaroni, A. M., Ljubenkov, P. A., Kornak, J., Cobigo, Y., Datta, S., Marx, G., Walters, S. M., Chiang, K., Olney, N., Elahi, F. M., et al. (2019) · Brain · doi:10.1093/brain/awy319 · Cited by 105
Self-citationClinical Use and Utility of Amyloid Imaging
Barthel, H., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185017 · Cited by 102
Treatment of Frontotemporal Dementia
Tsai, R. M., & Boxer, A. L. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0319-0 · Cited by 115
Self-citationFrontotemporal Lobar Degeneration: A Clinical Approach
Karageorgiou, E., & Miller, B. L. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381735 · Cited by 107
Self-citationKuruppu, D. K., & Matthews, B. R. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359320 · Cited by 106
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 94
Ducharme, S., Price, B. H., Larvie, M., Dougherty, D. D., & Dickerson, B. C. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101248 · Cited by 98
Primary progressive aphasia and the language network
Mesulam, M. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d87df · Cited by 85
Self-citationJokel, R., Meltzer, J., Dr, J., Dm, L., Jc, J., An, E., & D.T., C. (2017) · Journal of Communication Disorders · doi:10.1016/j.jcomdis.2017.04.002 · Cited by 71
Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J. H., Boxer, A. L., Dale, M. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694872 · Cited by 92
Self-citationAtypical parkinsonian syndromes: a general neurologist's perspective
Deutschländer, A., Ross, O. A., Dickson, D. W., & Wszołek, Z. K. (2017) · European Journal of Neurology · doi:10.1111/ene.13412 · Cited by 88
Toward a glutamate hypothesis of frontotemporal dementia
Benussi, A., Alberici, A., Buratti, E., Ghidoni, R., Gardoni, F., Di Luca, M., Padovani, A., & Borroni, B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00304 · Cited by 90
Practical utility of amyloid and FDG-PET in an academic dementia center
Sánchez‐Juan, P., Ghosh, P. M., Hagen, J., Gesierich, B. G., Henry, M. L., Grinberg, L. T., O’Neil, J. P., Janabi, M., Huang, E. J., Trojanowski, J. Q., et al. (2013) · Neurology · doi:10.1212/wnl.0000000000000032 · Cited by 78
Self-citationWarmus, B. A., Sekar, D. R., McCutchen, E., Schellenberg, G. D., Roberts, R. C., McMahon, L. L., & Roberson, E. D. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3418-14.2014 · Cited by 82
Salience Network Resting-State Activity: Prediction of Frontotemporal Dementia Progression
Day, G. S., Farb, N. A. S., Tang-Wai, D. F., Masellis, M., Black, S. E., Freedman, M., Pollock, B. G., & Chow, T. W. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3258 · Cited by 73
Memantine: Updating a rare success story in pro-cognitive therapeutics
Tari, P. K., Parsons, C. G., Collingridge, G. L., & Rammes, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109737 · Cited by 78
Younes, K., & Miller, B. L. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.006 · Cited by 82
Self-citationRabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Teichmann, M., Lesoil, C., Godard, J., Vernet, M., Bertrand, A., Lévy, R., Dubois, B., Lemoine, L., Truong, D. Q., Bikson, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24766 · Cited by 76
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationClinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72
Frontotemporal dementia and primary progressive aphasia, a review
Kirshner, H. S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s38821 · Cited by 75
Cunningham, E. L., McGuinness, B., Herron, B. M., & Passmore, A. P. (2015) · PubMed · Cited by 68
Sinha, K., Sun, C. E., Kamari, R., & Bettermann, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.003 · Cited by 63
Motor neuron disease-frontotemporal dementia: a clinical continuum
Devenney, E. M., Vucic, S., Hodges, J. R., & Kiernan, M. C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1034108 · Cited by 62
Behavioral Variant Frontotemporal Dementia
Seeley, W. (2019) · Continuum · doi:10.1212/con.0000000000000698 · Cited by 17
Rosen, H. J., Boeve, B. F., & Boxer, A. L. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12004 · Cited by 55
Self-citationHuber, N., Korhonen, S., Hoffmann, D. B., Leskelä, S., Rostalski, H., Remes, A. M., Honkakoski, P., Solje, E., & Haapasalo, A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01384-8 · Cited by 58
Right Temporal Lobe Atrophy: A Case That Initially Presented as Excessive Piety
Everhart, D. E., Watson, E. M., Bickel, K. L., & Stephenson, A. J. (2015) · The Clinical Neuropsychologist · doi:10.1080/13854046.2015.1104387 · Cited by 54
The power of neuroimaging biomarkers for screening frontotemporal dementia
McMillan, C. T., Avants, B., Cook, P. A., Ungar, L., Trojanowski, J. Q., & Grossman, M. (2014) · Human Brain Mapping · doi:10.1002/hbm.22515 · Cited by 58
Self-citationInvestigation of the role of rare TREM2 variants in frontotemporal dementia subtypes
Thelen, M., Razquín, C., Hernández, I., Gorostidi, A., Sánchez‐Valle, R., Ortega‐Cubero, S., Wolfsgruber, S., Drichel, D., Fließbach, K., Duenkel, T., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.018 · Cited by 53
Advances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
Self-citationMemantine for Fragile X–Associated Tremor/Ataxia Syndrome
Seritan, A. L., Nguyen, D. V., Mu, Y., Tassone, F., Bourgeois, J. A., Schneider, A., Cogswell, J. B., Cook, K., Leehey, M. A., Grigsby, J., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08546 · Cited by 53
Four-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 55
Self-citationLong-term follow-up in primary progressive aphasia: Clinical course and health care utilisation
Riedl, L., Last, D., Danek, A., & Diehl-Schmid, J. (2014) · Aphasiology · doi:10.1080/02687038.2014.904497 · Cited by 46
Bensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 50
Behavioural-variant frontotemporal dementia: An update
Piguet, O., & Hodges, J. R. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn70100003 · Cited by 50
Harciarek, M., Sitek, E. J., & Kertesz, A. (2014) · Aphasiology · doi:10.1080/02687038.2014.904498 · Cited by 51
Gerstenecker, A. T. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx093 · Cited by 46
Diagnosis and Treatment of Corticobasal Degeneration
Armstrong, M. J. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0282-1 · Cited by 44
Pharmacological Treatments for Frontotemporal Dementias
Nardell, M., & Tampi, R. (2014) · American Journal of Alzheimers Disease & Other Dementias · doi:10.1177/1533317513507375 · Cited by 32
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road
Sawyer, R. P., Rodriguez-Porcel, F., Hagen, M., Shatz, R., & Espay, A. J. (2017) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-017-0052-4 · Cited by 40
Depression in Parkinson's Disease: A Narrative Review
Chikatimalla, R., Dasaradhan, T., Koneti, J., Cherukuri, S. P., Kalluru, R., & Gadde, S. (2022) · Cureus · doi:10.7759/cureus.27750 · Cited by 45
Nilsson, C. F., Waldö, M. L., Nilsson, K. H., Santillo, A. F., & Vestberg, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094901 · Cited by 38
New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia
Amin, S., Carling, G., & Gan, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.001 · Cited by 37
Finger, E. C., Berry, S. M., Cummings, J. L., Coleman, K. K. L., Hsiung, G. R., Feldman, H., & Boxer, A. L. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0427-2 · Cited by 38
Self-citationNew Approaches to the Treatment of Frontotemporal Dementia
Neylan, K. D., & Miller, B. L. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01380-6 · Cited by 42
Self-citationWong, C. W. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0372-3 · Cited by 37
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Le, C., & Finger, E. (2021) · CNS Drugs · doi:10.1007/s40263-021-00854-5 · Cited by 26
Memantine for the treatment of frontotemporal dementia: a meta-analysis
Kishi, T., Matsunaga, S., & Iwata, N. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s94430 · Cited by 35
Burden of caregivers of patients with frontotemporal lobar degeneration – a scoping review
Karnatz, T., Monsees, J., Wucherer, D., Michalowsky, B., Zwingmann, I., Halek, M., Hoffmann, W. U., & Thyrian, J. R. (2019) · International Psychogeriatrics · doi:10.1017/s1041610219000176 · Cited by 37
Trieu, C., Gossink, F., Stek, M., Scheltens, P., Pijnenburg, Y., & Dols, A. (2020) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000217 · Cited by 32
Shiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanović, V., Staff, R. T., Murray, A. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191173 · Cited by 34
Korb, M. K., Peck, A., Alfano, L. N., Berger, K. I., James, M. K., Ghoshal, N., Healzer, E., Henchcliffe, C., Khan, S., Mammen, P. P. A., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02172-5 · Cited by 35
Self-citationAlberici, A., Archetti, S., Pilotto, A., Premi, E., Cosseddu, M., Bianchetti, A., Semeraro, F., Salvetti, M., Muiesan, M. L., Padovani, A., et al. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1683-y · Cited by 36
Kanemoto, H., Kazui, H., Suzuki, Y., Sato, S., Kishima, H., Yoshimine, T., & Yoshiyama, K. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.001 · Cited by 33
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis
Mahoney, C., Ahmed, R. M., Huynh, W., Tu, S., Rohrer, J. D., Bedlack, R., Hardiman, O. M., & Kiernan, M. C. (2021) · CNS Drugs · doi:10.1007/s40263-021-00820-1 · Cited by 38
Devenney, E. M., Ahmed, R. M., & Hodges, J. R. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00015-7 · Cited by 40
Progressive Supranuclear Palsy and Corticobasal Degeneration
Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_11 · Cited by 33
Therapeutic trial design for frontotemporal dementia and related disorders
Desmarais, P., Rohrer, J. D., Nguyên, Q. D., Herrmann, N., Stuss, D. T., Lang, A. E., Boxer, A. L., Dickerson, B. C., Rosen, H. J., Swieten, J. C. V., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318603 · Cited by 35
Self-citationA Clinical Guide to Frontotemporal Dementias
Ljubenkov, P. A., & Miller, B. L. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160018 · Cited by 36
Self-citationBashir, S., Aiman, A., Shahid, M., Chaudhary, A. A., Sami, N., Basir, S. F., Hassan, M. I., & Islam, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102276 · Cited by 31
Vuksanović, V., Staff, R. T., Ahearn, T. S., Murray, A. D., & Wischik, C. M. (2018) · International Journal of Neural Systems · doi:10.1142/s0129065718500557 · Cited by 31
Precision Medicine for Frontotemporal Dementia
Liu, M.-N., Lau, C.-I., & Lin, C.-P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00075 · Cited by 20
Diagnosing, monitoring and managing behavioural variant frontotemporal dementia
Piguet, O., Kumfor, F., & Hodges, J. R. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01458 · Cited by 32
Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review
Buoli, M., Serati, M., Caldiroli, A., Galimberti, D., Scarpini, E., & Altamura, A. (2017) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988717700506 · Cited by 25
Logroscino, G., Imbimbo, B. P., Lozupone, M., Sardone, R., Capozzo, R., Battista, P., Zecca, C., Dibello, V., Giannelli, G., Bellomo, A., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1598377 · Cited by 30
Therapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 26
Overcoming apathy in frontotemporal dementia: challenges and future directions
Johnson, E., & Kumfor, F. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2018.01.022 · Cited by 22
Cholinergic depletion and basal forebrain volume in primary progressive aphasia
Schaeverbeke, J., Evenepoel, C., Bruffaerts, R., van Laere, K., Bormans, G., Dries, E., Tousseyn, T., Nelissen, N., Peeters, R., Vandenbulcke, M., et al. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.027 · Cited by 25
Binney, R. J., Pankov, A., Marx, G., He, X., McKenna, F., Staffaroni, A. M., Kornak, J., Attygalle, S., Boxer, A. L., Schuff, N., et al. (2017) · Brain and Behavior · doi:10.1002/brb3.675 · Cited by 21
Self-citationData-driven regions of interest for longitudinal change in frontotemporal lobar degeneration
Pankov, A., Binney, R. J., Staffaroni, A. M., Kornak, J., Attygalle, S., Schuff, N. W., Weiner, M. W., Kramer, J. H., Dickerson, B. C., Miller, B. L., et al. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.08.002 · Cited by 23
Self-citationCombined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23
Kim, Y., Kang, D. W., Kim, G. H., Kim, K. W., Kim, H. J., Na, S., Park, K. H., Park, Y. H., Byeon, G., Suh, J., et al. (2025) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2025.24.1.1 · Cited by 23
Spehl, T. S., Frings, L., Hellwig, S., Weiller, C., Hüll, M., Meyer, P. T., & Amtage, F. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000554 · Cited by 22
Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease
Kurz, A., & Grimmer, T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.945907 · Cited by 22
Sleep and orexin: A new paradigm for understanding behavioural-variant frontotemporal dementia?
Hwang, Y. T., Piguet, O., Hodges, J. R., Grunstein, R. R., & Burrell, J. R. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101361 · Cited by 24
Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes
Miller, J. B., Banks, S. J., Léger, G. C., & Cummings, J. L. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-12 · Cited by 21
Treatment of the behavioral variant of frontotemporal dementia: a narrative review
Gambogi, L. B., Guimarães, H. C., de Souza, L. C., & Caramelli, P. (2021) · Dementia & Neuropsychologia · doi:10.1590/1980-57642021dn15-030004 · Cited by 25
Clinical guidelines «Cognitive disorders in the elderly and senile persons»
Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 22
A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice
Kim, Y., Rosenberg, P., & Oh, E. S. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000492151 · Cited by 11
Advances in the treatment and management of frontotemporal dementia
Benussi, A., & Borroni, B. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2228491 · Cited by 19
Pharmacotherapy for Frontotemporal Dementia
Khoury, R., Liu, Y., Sheheryar, Q., & Grossberg, G. T. (2021) · CNS Drugs · doi:10.1007/s40263-021-00813-0 · Cited by 22
Metadata
- Authors
- Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., Koestler, M., Shapira, J., Sullivan, K., Klepac, K., Lipowski, K., Ullah, J., Fields, S., Kramer, J. H., Merrilees, J., Neuhaus, J., Mesulam, M. M., & Miller, B. L.
- Affiliations
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University of North Carolina at Chapel Hill (US)
- University of Pennsylvania (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Northwestern University (US)
- Case Western Reserve University (US)
- Texas Tech University (US)
- Corresponding author
- Boxer, Adam L
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 12
- Issue
- 2
- Pages
- 149-156
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC3756890
- OpenAlex
- W2106046611
- Cited by
- 228
- References
- 31
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 17 · 2020: 15 · 2019: 21 · 2018: 15 · 2017: 22 · 2016: 21 · 2015: 23 · 2014: 24 · 2013: 18
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Larry L. Hillblom Foundation (P50 AG1657303)
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Agouron Institute
- TauRx Pharmaceuticals
- National Institutes of Health (UL1TR000150)
- Genentech
- University of California, San Francisco (P50 AG023501, P01AG019724)
- National Institute on Aging (P50AG1657303, R01AG031278, P30AG013854, R01AG038791, P01AG019724, P50AG023501)
- National Institute on Deafness and Other Communication Disorders (R01DC008552)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- memantine, frontotemporal lobar degeneration, behavioral variant frontotemporal dementia, semantic dementia, neuropsychiatric symptoms, NPI, Clinical Global Impression of Change, treatment efficacy, drug tolerability
- MeSH terms
- Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Memantine, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Retrospective Studies, Chi-Square Distribution, Treatment Outcome, Excitatory Amino Acid Antagonists, Frontotemporal Lobar Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
